Program
ACE723
A development code.
Its studies are mostly in Carcinoma, Hepatocellular, led by Acepodia Biotech.
Furthest: phase 1, since Sep 29, 20261 company-led study, 1 open or runningNext primary completion: May 2030 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Acepodia Biotech | 11 open or running | phase 1since Sep 29, 2026 | Sep 29, 2026 | May 2030phase 1 · NCT07861425 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 29, 2026First study: phase 1 study in Carcinoma, HepatocellularFirst studyNCT07861425 · 70 planned · China
Ahead
- May 2030Primary completion: phase 1 study in Carcinoma, HepatocellularNCT07861425
TargetBeta
GPC3 →read by rule
“A Phase 1 Clinical Trial of ACE723, A Dual-Payload Antibody Drug Conjugate Targeting Glypican-3 (GPC-3), in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Who Have Failed or Progressed on Standard Immune Checkpoint Inhibitor-Containing Systemic Therapies”study text, by rule · the study
Other programs on GPC3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033rule | BeOne Medicines | phase 3 | 3 |
| codrituzumab | Hoffmann-La Roche | phase 2 | 3 |
| GPC3-targeted Plasmid DNA Vaccine NWRD06rule | Newish Biotech (Wuxi) | phase 2 | 2 |
| Actinium Ac 225 GPC3-targeted Peptide RYZ801 | Bristol-Myers Squibb | phase 2 | 1 |
| Anti-GPC3 T Cell-engaging Antibody AZD9793 | AstraZeneca | phase 2 | 1 |
| Anti-GPC3 Antibody-drug Conjugate ZW251rule | Zymeworks | phase 1 | 1 |
| Anti-GPC3 Antibody-drug Conjugate ABBV-324 | AbbVie | phase 1 | 1 |
| Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926rule | Bayer | phase 1 | 1 |
| TQB6426rule | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07861425Carcinoma, Hepatocellular · China | 1 | Not yet recruiting | May 2030 | 70 |
How it is read
Names in the registry
- “ACE723”, 1 entry
Codes read as this program: ACE723.
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.